This is an old revision of this page, as edited by Bunnyhop11 (talk | contribs) at 17:46, 30 August 2011 (dab pdt). The present address (URL) is a permanent link to this revision, which may differ significantly from the current revision.
Revision as of 17:46, 30 August 2011 by Bunnyhop11 (talk | contribs) (dab pdt)(diff) ← Previous revision | Latest revision (diff) | Newer revision → (diff) Pharmaceutical compoundClinical data | |
---|---|
Routes of administration | IV |
ATC code |
|
Legal status | |
Legal status |
|
Identifiers | |
IUPAC name
| |
CAS Number |
|
PubChem CID | |
UNII | |
CompTox Dashboard (EPA) | |
Chemical and physical data | |
Formula | C38H41N5O9 |
Molar mass | 711.76 g/mol g·mol |
3D model (JSmol) | |
SMILES
| |
(verify) |
Talaporfin (INN, also known as aspartyl chlorin, mono-L-aspartyl chlorine e6, NPe6, or LS11) is a photosensitizer used in photodynamic therapy (PDT).
It absorbs red light at 664nm normally provided by a laser tuned to this wavelength.
It was approved in Japan (in 2004) for PDT of lung cancer and marketed as Laserphyrin.
References
- http://journals.lww.com/jto/Fulltext/2006/06000/Photodynamic_Therapy__PDT__for_Lung_Cancers.18.aspx "Photodynamic Therapy (PDT) for Lung Cancers" 2006
- http://meeting.ascopubs.org/cgi/content/abstract/24/18_suppl/7229 "Photodynamic therapy using Laserphyrin for centrally located early stage lung cancer" 2006
This antineoplastic or immunomodulatory drug article is a stub. You can help Misplaced Pages by expanding it. |